Biomarin Pharmaceutical Inc.
- BID
51.88
- ASK
51.98
- 136 Units1,289 Units
- 07/21, 21:59:58 PM
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
5.54%
Market Cap
10.02 Bil.
P/E Ratio
32.93
Dividend Yield
0.00 %
Earnings per Share
1.60 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 51.88 G | 0 Units |
| PRICE DETERMINATION TIME | 07/21/2026 / 09:55:48 PM | |
| DAILY VOLUME (UNITS) | 0 | |
| DAILY HIGH / LOW | 52.34 | 51 |
| PREV. DAY'S PRICE | 51.82 | (07/20) |
| CHANGE DAY BEFORE | +0.06 | 0.12 % |
| 52 WEEK HIGH / LOW | 55.38 (02/23) | 42.34 (05/18) |
Key Figures (in EUR)
| 2023 | 2024 | 2025 | 2026e | 2027e | |
|---|---|---|---|---|---|
EARNINGS PER SHARE | 0.81 | 2.04 | 1.60 | 4.33 | 5.73 |
DIVIDENDS PER SHARE | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
DIVIDEND YIELD IN % | 0.00 % | 0.00 % | 0.00 % | - | - |
DIVIDEND GROWTH IN % | - | - | - | - | - |
PRICE - EARNINGS RATIO | 110.19 | 29.78 | 32.93 | 12.04 | 9.10 |
PRICE - BOOK RATIO | 3.67 | 2.22 | 1.88 | - | - |
PRICE - SALES RATIO | 7.64 | 4.55 | 3.62 | - | - |
PRICE - CASH FLOW RATIO | 116.00 | 22.57 | 14.17 | - | - |
Master Data
| WKN | 924801 |
| ISIN | US09061G1013 |
| SYMBOL | BM8 |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | Biomarin Pharmaceutical |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | US Dollar |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | 193.28 Mil. |
| MARKET CAPITALISATION | 10.02 Bil. |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | -0.08 % | 8.34 % | 11.39 % | 7.80 % | 5.54 % | -33.55 % | -23.88 % | 2.33 % |
| HIGH | 52.46 | 52.82 | 52.82 | 55.38 | 55.38 | 90.58 | 107.66 | 55.38 |
| LOW | 50.52 | 47.06 | 42.34 | 42.34 | 42.34 | 42.34 | 42.34 | 42.34 |
Dividende
pro Aktie
Biomarin Pharmaceutical does not deliver dividend information
Company profile
BioMarin Pharmaceutical, Inc. is a global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. The company has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.
Structured products for Biomarin Pharmaceutical Inc.
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
No company events available.